Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - January 22, 2025 544 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KATHERINE study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR FDA Approves Pembrolizumab with Chemotherapy for Primary Advanced or Recurrent Endometrial... July 24, 2024 The Childhood Cancer Data Initiative: Transforming the Pediatric Cancer Landscape through... August 15, 2019 Sacituzumab Govitecan Prolongs Survival in Relapsed or Refractory Metastatic Triple Negative... April 27, 2021 37-Year-Old Mom Breaks American Marathon Record January 21, 2022 Load more HOT NEWS El cáncer en mi comunidad: Ampliar el acceso a las pruebas... Spending Review 2020 – Steps in the right direction, but opportunities... Marine Runs Five Marathons in Five Days to Help Fund Sister’s... Sacituzumab Govitecan Approved for Metastatic Triple-Negative Breast Cancer
